Epilepsy is a chronic non-communicable disease of the brain that affects people of all ages. Epilepsy can start at any age, but usually starts either in childhood or in people over 60. Seizures can affect people in different ways, depending on which part of the brain is involved. Possible symptoms of epilepsy include uncontrollable jerking and shaking, called ‘fit’, loss of awareness and staring blankly into space, stiffness, strange sensations in the stomach, unusual smell or taste, tingling sensation in arms or legs, and collapsing. The most commonly used treatment methods of epileptic seizures include anti-epileptic drug therapy, brain surgery, vagus nerve stimulation, deep brain stimulation, and ketogenic diet.
Epileptic Seizures Treatment Market – Impact of Coronavirus (Covid-19) Pandemic
The demand for epileptic seizures treatment remained same during COVID-19 pandemic, as it is observed that epilepsy and COVID-19 infection does not have a direct connection. According to the International League against Epilepsy, there is no direct evidence that the coronavirus infection can directly cause epilepsy. However, like most of the infections can cause high fever, breathing difficulties, and other problems with normal functioning, being infected can result in a person who is susceptible to epilepsy, might suffer breakthrough episodes. Although, disruption in the supply of drugs have slightly impacted the epileptic seizures treatment market negatively.
The epileptic seizures treatment market is estimated to be valued at US$ 3.0 billion in 2020 and is expected to exhibit a CAGR of 5.4% during the forecast period (2020-2027).
Figure 1. Global Epileptic Seizures Treatment Market Share (%) Analysis, By Region, 2027
Rising clinical trials and increasing drug approvals & launches are expected to boost growth of the epileptic seizures treatment market
Rising clinical trials for new drug for the treatment of epileptic seizures is expected to accelerate the epileptic seizures treatment market growth over the forecast period. For instance, in January 2019, Xenon Pharmaceuticals Inc. in collaboration with NCGS, Inc. initiated a clinical study on the drug, XEN1101 for the treatment of focal epilepsy. The trial aims to evaluate the clinical efficacy, safety, and tolerability of XEN1101 administered as adjunctive treatment in adult patients aged 18 to 75 years diagnosed with focal epilepsy. In this trial, 300 patients are involved, who are being treated with XEN1101 and placebo capsules. This clinical trial is in phase 2 and is expected to complete in June 2022.
Furthermore, increasing drug approvals and launches for the treatment of epileptic seizures is expected to drive the global epileptic seizures treatment market growth. For instance, Eisai Co., Ltd. announced that they received a New Drug Approval for its in-house discovered and developed anti-epileptic drug (AED) Fycompa (perampanel) from the China National Medical Products Administration (NMPA) for use in an adjunctive treatment of partial onset seizures (with or without secondarily generalized seizures) in epilepsy patients 12 years of age and older. Hence, such approvals are expected to positively impact the global epileptic seizures treatment market growth.
Epileptic Seizures Treatment Market – Restraints
Anti-epileptic drugs exhibit mild or adverse neurological side effects occasionally, however they can be fatal. The adverse reactions and risks vary with each medication. Majority of antiepileptic drugs have the potential to cause an allergic reaction. These drugs indirectly increase the risk of conditions such as aggressive behavior and depression. In pregnant women, anti-epileptic drugs can also harm the fetus. According to the Journal of Family Practice the side effects of anti-epileptic drugs include – Phenytoin causes a pattern of defects collectively called the Fetal Hydantoin Syndrome (FHS) characterized by variable degrees of hypoplasia and ossification of the distal phalanges and craniofacial abnormalities. Moreover, anticonvulsants, particularly hydantoins and barbiturates are associated with hemorrhagic diseases in newborns. Therefore, such severe side effects are expected to hinder the epileptic seizures treatment market growth over the forecast period.
| Report Coverage | Details | ||
|---|---|---|---|
| Base Year: | 2019 | Market Size in 2020: | US$ 3.0 Bn |
| Historical Data for: | 2017 to 2019 | Forecast Period: | 2020 to 2027 |
| Forecast Period 2020 to 2027 CAGR: |
5.4% |
2027 Value Projection: | US$ 4.5 Bn |
| Geographies covered: |
|
||
| Segments covered: |
|
||
| Companies covered: |
Novartis AG, GlaxoSmithKline Plc, Johnson & Johnson Service, Inc., Teva Pharmaceutical Industries Ltd., Pfizer, Inc., Sanofi S.A., Mylan N.V., Bausch Health Companies Inc., UCB S.A., Eisai Co. Ltd., Abbott Laboratories, Sumitomo Dainippon Pharma Co., Ltd., GW Pharmaceuticals Plc, Marinus Pharmaceuticals, Inc., H. Lundbeck A/S, and Takeda Pharmaceutical Co., Ltd. |
||
| Growth Drivers: |
|
||
| Restraints & Challenges: |
|
||
Epileptic Seizures Treatment Market – Regional Analysis
North America is estimated to hold dominant position in the global epileptic seizures treatment market in 2020 due to increasing product launches and product approvals by regulatory authorities in the region. For instance, in November 2019, SK Life Science, Inc. announced that the U.S. Food and Drug Administration (FDA) approved XCOPRI (cenobamate tablets) for the treatment of partial-onset seizures in adults. Similarly, in August 2019, Dr. Reddy's Laboratories launched generic anti-epileptic Vigabatrin powder for oral solution in the U.S. market.
Moreover, Asia Pacific epileptic seizures treatment market is expected to witness significant growth during the forecast period, owing to increasing agreements between the key players for supply of anti-epileptic drugs in Asia Pacific region. For instance, in December 2017, Hydroponics Company entered into agreement with BOL Pharma to supply BOL Pharma’s medicinal cannabis products in Australia. BOL Pharma’s medicinal cannabis products are intended to be used for the treatment of patients suffering from epilepsy and other neurological disorders.
Figure 2. Global Epileptic Seizures Treatment Market Value (US$ Bn) & Y-o-Y Growth (%), 2016-2027
Epileptic Seizures Treatment Market - Competitive Landscape
Key players operating in the global epileptic seizures treatment market include Novartis AG, GlaxoSmithKline Plc, Johnson & Johnson Service, Inc., Teva Pharmaceutical Industries Ltd., Pfizer, Inc., Sanofi S.A., Mylan N.V., Bausch Health Companies Inc., UCB S.A., Eisai Co. Ltd., Abbott Laboratories, Sumitomo Dainippon Pharma Co., Ltd., GW Pharmaceuticals Plc, Marinus Pharmaceuticals, Inc., H. Lundbeck A/S, and Takeda Pharmaceutical Co., Ltd.
Epilepsy is a chronic disorder that causes unprovoked and recurrent seizures. A seizure is a sudden rush of electrical activity in the brain. Epilepsy is associated with disrupted activities in the brain called seizures, which affects the central nervous system. Epilepsy is categorized into generalized seizures and partial seizures based on the areas affected in the brain. An increasing number of epilepsy cases is expected to drive growth of the global epileptic seizures treatment market. For instance, according to the study by Epilepsy Action Australia statistics in 2017, around 50 million people globally had epilepsy with around 80% of the people living in emerging economies such as India, Brazil, and China.
Moreover, increasing launches of drugs for treatment of epilepsy is expected to create conducive environment for the market growth. For instance, in 2016, UCB Pharma Limited received the U.S. FDA approval for Briviact, for the treatment of patients with partial onset of seizures. Moreover, Mylan launched generic, Felbatol tablets for the treatment of epileptic seizures, in the U.S. after receiving approval from the U.S. Food & Drug Administration in 2016. These factors are expected to boost the market growth over the forecast period.
Market Dynamics
The increasing prevalence of epilepsy in adults and children, across the globe is expected to drive growth of the epileptic seizures treatment market during the forecast period. According to the WHO, around one-third of children with epilepsy can be assigned to a specific epilepsy syndrome, as defined by the most recently proposed system for organization of epilepsy syndrome. According to the Society of Neuroscience, in 2015, epilepsy affected around 10.5 million children worldwide, and the types and severity of the disorder varied significantly. Moreover, according to the American Academy of Pediatrics data published in April 2017, epilepsy affects 0.5% to 1% of children globally, and is the most frequently occurring chronic neurologic condition in childhood.
However, non‐conventional anti-epileptic treatments and non‐pharmacological approaches can potentially help in reduction of seizures or anti-epileptic drug toxicity. For instance, there has been increasing preference for alternative therapy for epilepsy such as corticosteroids, immunoglobulins, melatonin, and vitamins for treating children. Other than supplemental therapy, there are certain techniques that can help reduce epileptic seizures such as avoidance technique, which involves avoiding activities that can induce a seizure such as flickering lights, listening to specific type or piece of music, eating, reading, and immersion in hot water, chess playing, or brushing hair. Thus, these factors are expected to restrain the epileptic seizures treatment market growth. Other non‐pharmacological treatments for epilepsy in children include herbal medicine, homeopathy, yoga, aromatherapy, and coping strategies.
Key features of the study:
Detailed Segmentation:
“*” marked represents similar segmentation in other categories in the respective section.
Joining thousands of companies around the world committed to making the Excellent Business Solutions.
View All Our Clients